Xenon Pharmaceuticals Files 8-K for Shareholder Votes & Exhibits

TL;DR

Xenon Pharma filed an 8-K for shareholder votes and exhibits - standard stuff.

AI Summary

Xenon Pharmaceuticals Inc. filed an 8-K on June 4, 2024, to report on matters submitted to a vote of security holders and to file financial statements and exhibits. The filing does not contain specific details on the votes or financial statements themselves, but indicates their submission.

Why It Matters

This filing indicates that Xenon Pharmaceuticals has held or is holding votes for its security holders and is submitting required financial documents, which are standard corporate governance and reporting procedures.

Risk Assessment

Risk Level: low — This is a routine filing for corporate governance and reporting, not indicating any specific new risks or material events.

Key Players & Entities

• Xenon Pharmaceuticals Inc. (company) — Registrant
• June 4, 2024 (date) — Date of earliest event reported
• 200 - 3650 Gilmore Way Burnaby, British Columbia, Canada V5G 4W8 (address) — Principal Executive Offices

FAQ

Filing Documents

• xene-20240604.htm (8-K) — 114KB
• xene-ex10_1.htm (EX-10.1) — 332KB
• 0000950170-24-069318.txt ( ) — 615KB
• xene-20240604.xsd (EX-101.SCH) — 30KB
• xene-20240604_htm.xml (XML) — 5KB

07

Item 5.07 Submission of Matters to a Vote of Security Holders On June 4, 2024, Xenon Pharmaceuticals Inc. (the "Company") held its 2024 Annual Meeting of Shareholders (the "Annual Meeting"). At the Annual Meeting, 68,502,857 of the Company's common shares, or approximately 90.78% of the total common shares entitled to vote, were present or represented by proxies and voted on the following four proposals, each of which is described in more detail in the Company's Definitive Proxy Statement on Schedule 14A, filed with the Securities and Exchange Commission and the securities commissions in British Columbia, Alberta and Ontario on or after April 26, 2024 (the "Proxy Statement"): Proposal One – Election of Directors . The following nominees were elected as directors to serve until the 2025 annual meeting of shareholders or until their respective successors are duly elected and qualified: For Against Broker Non-Votes Dawn Svoronos 61,455,358 4,487,857 2,559,642 Gillian Cannon 65,895,891 47,324 2,559,642 Steven Gannon 65,709,645 233,570 2,559,642 Elizabeth Garofalo 62,307,376 3,635,839 2,559,642 Justin Gover 65,932,083 11,132 2,559,642 Patrick Machado 63,197,819 2,745,396 2,559,642 Ian Mortimer 65,768,424 174,791 2,559,642 Gary Patou 64,901,660 1,041,555 2,559,642 Proposal Two – Advisory Vote on Compensation of Named Executive Officers ("Say-on-Pay"). The compensation of the Company's named executive officers, on an advisory basis, was approved as follows: For Against Abstain Broker Non-Votes 63,950,064 1,979,402 13,742 2,559,642 Proposal Three – Amendments to Amended and Restated 2014 Equity Plan. The proposed amendments to the Company's Amended and Restated 2014 Equity Plan, including to increase the maximum number of common shares available for issuance thereunder by 5,200,000, were approved as follows: For Against Abstain Broker Non-Votes 63,107,128 2,823,056

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits. Pursuant to the rules and regulations of the Securities and Exchange Commission, the attached exhibit is deemed to have been furnished to, but not filed with, the Securities and Exchange Commission: Exhibit Number Description 10.1 Amended and Restated 2014 Equity Incentive Plan and form of share option agreement used thereunder. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. XENON PHARMACEUTICALS INC. Date: June 5, 2024 By: /s/ Sherry Aulin Sherry Aulin Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR